Vegetable oil import down 16 per cent in March to 9.98 lakh tonne: SEA

India’s vegetable oil imports witnessed a 16% decline in March, totaling 9.98 lakh tonnes, primarily due to a significant drop in crude sunflower oil shipments. During the first five months of the 2024-25 oil marketing year, total vegetable oil imports marginally decreased. Palm oil imports sharply decreased, while soft oil imports jumped during the same […]

Portfolio strategy now needs rebalancing; avoid chasing froth: Jigar Mistry

Jigar Mistry of Buoyant Capital discusses the Indian market’s potential upswing, cautioning against oversimplification due to global factors like tariffs and recessionary pressures. He highlights the nuanced impacts of trade dynamics and suggests a calibrated approach. Mistry advises focusing on large-cap stocks and specific sectors like banking, financials, and healthcare, while remaining cautious about the […]

Muthoot Finance shares fall 14% in two-day rout on RBI tightening gold loan rules

Muthoot Finance shares plummeted after the Reserve Bank of India (RBI) announced forthcoming comprehensive regulations for gold-backed loans, triggering a selloff. The new rules include a uniform Loan-to-Value (LTV) cap of 75% and stricter monitoring of gold loans for income generation. Other lenders with gold loan exposure, like Manappuram Finance and IIFL Finance, also experienced […]

Largecaps fairly valued, but mid & smallcaps still need correction: Shreyash Devalkar

Axis MF’s Shreyash Devalkar suggests largecaps are fairly priced, while mid and smallcaps, despite growth potential, need further valuation correction. He notes earning downgrades are following stock price falls, with FY26 downgrades largely priced in. Devalkar favors financial services and pharmaceuticals, reducing exposure to export-oriented and industrial names, emphasizing a stock-picker market driven by risk-reward […]

Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug

Biocon’s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon’s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.

Positive Breakout: These 5 stocks cross above 200 DMAs

In the Nifty500 pack, five stocks’ close prices crossed above their 200 DMA (Daily Moving Averages) on April 9, according to stockedge.com’s technical scan data. The 200-day DMA is used as a key indicator by traders for determining the overall trend in a particular stock. As long as the stock is priced above the 200-day […]

Fed’s Goolsbee: Rate cuts still possible if economy gets back on track

Chicago Fed President Austan Goolsbee suggests a cautious approach to monetary policy amidst economic uncertainty fueled by trade tariffs. He acknowledges the tariffs’ potential stagflationary impact, making policy responses complex. While not ruling out future rate adjustments, Goolsbee emphasizes the need to assess the economy’s reaction to these tariffs.